On the other hand, skeletal muscle cells contain aldosterone receptors and aldosterone blockade has also been shown to markedly affect the ability of CKD patients to shift potassium into cells when angiotensin converting enzyme inhibitors are used concurrently and is an important reason why patients with CKD develop hyperkalemia with dual renin-angiotensin-aldosterone axis blockade. The gene discussed is NR3C2; the disease is chronic kidney disease.